Exelixis Has Renewed Momentum Heading Into 2021

 
• By Jessica Merrill
  
Cancer cells on scientific background.3d illustration
Exelixis' Cabometyx won approval for first-line RCC combined with BMS' Opdivo last month, raising revenue expectations. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip